Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions.
Shuting LiHongjie WangShijun XiongJing LiuShuming SunPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
Currently, multiple myeloma (MM) is a prevalent hematopoietic system malignancy, known for its insidious onset and unfavorable prognosis. Recently developed chemotherapy drugs for MM have exhibited promising therapeutic outcomes. Nevertheless, to overcome the shortcomings of traditional clinical drug treatment, such as off-target effects, multiple drug resistance, and systemic toxicity, targeted drug delivery systems are optimizing the conventional pharmaceuticals for precise delivery to designated sites at controlled rates, striving for maximal efficacy and safety, presenting a promising approach for MM treatment. This review will delve into the outstanding performance of antibody-drug conjugates, peptide-drug conjugates, aptamer-drug conjugates, and nanocarrier drug delivery systems in preclinical studies or clinical trials for MM and monitor their adverse reactions during treatment.
Keyphrases
- adverse drug
- multiple myeloma
- clinical trial
- cancer therapy
- drug induced
- emergency department
- drug delivery
- electronic health record
- gold nanoparticles
- randomized controlled trial
- oxidative stress
- stem cells
- metabolic syndrome
- bone marrow
- squamous cell carcinoma
- radiation therapy
- open label
- replacement therapy
- insulin resistance
- glycemic control
- magnetic nanoparticles
- phase iii
- double blind